A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis

European Journal of Neurology

Volumn 18, Issue 9, 2011, Pages 1122-1131

  Novotna, A ^a   Mares, J ^b   Ratcliffe, S ^c   Novakova, I ^d   Vachova, M ^e   Zapletalova, O ^f   Gasperini, C ^g   Pozzilli, C ^h   Cefaro, L ^h   Comi, G ⁱ   Rossi, P ⁱ   Ambler, Z ^j   Stelmasiak, Z ^k   Erdmann, A ^l   Montalban, X ^m   Klimek, A ⁿ   Davies, P ^o  

^a Pardubice Regional Hospital   (Czech Republic)

^b Neurologicka Klinika   (Czech Republic)

^c MAC UK Neuroscience Ltd   (United Kingdom)

^d MS Centrum   (Czech Republic)

^e MS centre of Hospital Teplice   (Czech Republic)

^f Klinika Hematoonkologie LF OU a FN Ostrava   (Czech Republic)

^g Reparto Neurologico LANCISI Day Hospital   (Italy)

^h SAPIENZA UNIVERSITY OF ROME   (Italy)

ⁱ SAN RAFFAELE HOSPITAL   (Italy)

^j CHARLES UNIVERSITY   (Czech Republic)

^k MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^l EDITH CAVELL HOSPITAL   (United Kingdom)

^m HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

ⁿ MEDICAL UNIVERSITY OF LODZ   (Poland)

^o NORTHAMPTON GENERAL HOSPITAL   (United Kingdom)

more..

Author keywords

Cannabidiol; Cannabinoids; Delta 9 tetrahydrocannabinol; Endocannabinoid system; Multiple sclerosis; Nabiximols; Sativex; Spasticity

Indexed keywords

ADAMANTANE DERIVATIVE; ANTICONVULSIVE AGENT; BACLOFEN; BENZODIAZEPINE DERIVATIVE; CANNABIS; DANTROLENE; NABIXOMOLS; NALTREXONE; PLACEBO; TIZANIDINE; TOLPERISONE; UNCLASSIFIED DRUG;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BACKACHE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EUPHORIA; FATIGUE; FEMALE; HEADACHE; HUMAN; INTENTION TO TREAT ANALYSIS; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; MUSCLE SPASM; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RELAPSE; RHINOPHARYNGITIS; SIDE EFFECT; SOMNOLENCE; SPASTICITY; TREATMENT OUTCOME; UPPER ABDOMINAL PAIN; URINARY TRACT INFECTION; VERTIGO; XEROSTOMIA;

ADULT; AGED; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MUSCLE SPASTICITY; PLANT EXTRACTS;

EID: 79953822342     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2010.03328.x     Document Type: Article

References (24)

1. Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler 2004; 10: 589-595.
2. Vukusic S, Van Bockstael V, Gosselin S, Confavreux C. Regional variations of multiple sclerosis prevalence in French farmers. J Neurol Neurosurg Psychiatry 2007; 78: 707-709.
3. Shakespeare DT, Boggild M, Young C. Anti-spasticity agents for multiple sclerosis (Cochrane Review). In: The Cochrane Library. 2001; Issue 3.
4. Smith CR, La Rocca NG, Giesser BS, Scheinberg LC. High-dose oral baclofen: experience in patients with multiple sclerosis. Neurology 1991; 41: 1829-1831.
5. Beard S, Hunn A, Wright J. Treatments for spasticity and pain in multiple sclerosis: a systematic review. Health Technol Assess 2003; 7: iii, ix-x, 1-111.
6. House of Lords Select Committee on Science and Technology. Cannabis: the scientific and medical evidence. Session 1997-98, 9th report.
7. 2 receptors. Pharmacol Ther 1997; 74: 129-180.
8. Pertwee RG. Neuropharmacology and therapeutic potential of cannabinoids. Addict Biol 2000; 5: 37-46.
9. Baker D, Pryce G, Croxford JL, et al. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 2000; 404: 84-87.
10. Russo EB, Guy GW. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 2006; 66: 234-246.
11. Wade D, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomised, placebo controlled study on 160 patients. Mult Scler 2004; 10: 434-441.
12. Collin C, Davies P, Mutiboko IK, Ratcliffe S for the Sativex Spasticity in MS Study Group. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol 2007; 14: 290-296.
13. Wade DT, Collin C, Stott C, Duncombe P. Meta-analysis of the efficacy and safety of Sativex, on spasticity in people with multiple sclerosis. Mult Scler 2010; 16: 707-714.
14. Farrar JT, Troxel AB, Stott C, Duncombe P, Jensen MP. Validity, reliability and clinical importance of change in a 0-10 numeric rating scale measure of spasticity: a post-hoc analysis of a randomized, double-blind, placebo-controlled trial. Clin Ther 2008; 30: 974-985.
15. Anwar K, Barnes MP. A pilot study of a comparison between a patient scored numeric rating scale and clinician scored measures of spasticity in multiple sclerosis. NeuroRehabilitation 2009; 24: 333-340.
16. Collin C, Ehler E, Waberzinek G, et al. A double-blind, randomised, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res 2010; 32: 451-459.
17. Baker D, Pryce G, Croxford JL, et al. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J 2001; 15: 300-302.
18. Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003; 9395: 1517-1526.
19. Zajicek JP, Sanders HP, Wright DE, et al. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12months follow up. J Neurol Neurosurg Psychiatry 2005; 76: 1664-1669.
20. Wade DT, Robson P, House H, Makela P, Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 2003; 17: 21-29.
21. Wade DT, Makela PM, House H, Bateman C, Robson P. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler 2006; 12: 639-645.
22. Vaney C, Heinzel-Gutenbrunner M, Jobin P, Tschopp F, et al. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler 2004; 10: 417-424.
23. Sackett DL. Turning a blind eye: why we don't test for blindness at the end of our trials. BMJ 2004; 328: 1136.
24. McQuay HJ, Derry S, Moore RA, Poulain P, Legout V. Enriched enrolment with randomised withdrawal (EERW): time for a new look at clinical trial design in chronic pain. Pain 2008; 135: 217-220.